Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-10-09
2009-12-08
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S296000
Reexamination Certificate
active
07629347
ABSTRACT:
The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signaling, the compounds represented as:wherein R1and R2are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1and Z2are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1is hydrogen, R2is a group other than hydrogen.
REFERENCES:
patent: 5155110 (1992-10-01), Connor et al.
patent: 5328914 (1994-07-01), Hocquaux et al.
patent: 5409930 (1995-04-01), Spada et al.
patent: 5480883 (1996-01-01), Spada et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5543520 (1996-08-01), Zimmermann
patent: 5612340 (1997-03-01), Zimmermann
patent: 5618829 (1997-04-01), Takayanagi et al.
patent: 5646153 (1997-07-01), Spada et al.
patent: 5656643 (1997-08-01), Spada et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5714493 (1998-02-01), Myers et al.
patent: 5721238 (1998-02-01), Heiker et al.
patent: 5736534 (1998-04-01), Arnold
patent: 5760041 (1998-06-01), Wissner et al.
patent: 5763470 (1998-06-01), Tang et al.
patent: 5795889 (1998-08-01), Spada et al.
patent: RE36256 (1999-07-01), Spada et al.
patent: 5932574 (1999-08-01), Baker
patent: 5958935 (1999-09-01), Davis et al.
patent: 6057320 (2000-05-01), Spada et al.
patent: 6069134 (2000-05-01), Roth et al.
patent: 6103728 (2000-08-01), Tang et al.
patent: 6127374 (2000-10-01), Bridges
patent: 6153617 (2000-11-01), Bridges
patent: 6169091 (2001-01-01), Cockerill et al.
patent: 6174889 (2001-01-01), Cockerill et al.
patent: 6180636 (2001-01-01), Traxler et al.
patent: 6184377 (2001-02-01), Gao
patent: 6207669 (2001-03-01), Cockerill et al.
patent: 6235746 (2001-05-01), Davis et al.
patent: 6251911 (2001-06-01), Bold et al.
patent: 6253168 (2001-06-01), Griffey et al.
patent: 6268391 (2001-07-01), Dickerson et al.
patent: RE37650 (2002-04-01), Myers et al.
patent: 6391874 (2002-05-01), Cockerill et al.
patent: 6432963 (2002-08-01), Hisamichi et al.
patent: 6525072 (2003-02-01), Tang et al.
patent: 6528509 (2003-03-01), Hale et al.
patent: 6562818 (2003-05-01), Bridges
patent: 6600037 (2003-07-01), Davis et al.
patent: 6635641 (2003-10-01), Bender et al.
patent: 6723726 (2004-04-01), Cockerill et al.
patent: 6828320 (2004-12-01), Cockerill et al.
patent: 2001/0021717 (2001-09-01), Potter et al.
patent: 2001/0027205 (2001-10-01), Camden
patent: 2001/0041964 (2001-11-01), Grass et al.
patent: 2001/0044451 (2001-11-01), Fraley et al.
patent: 2001/0047007 (2001-11-01), Fraley et al.
patent: 2001/0047364 (2001-11-01), Proctor
patent: 2001/0049092 (2001-12-01), Ekins et al.
patent: 2001/0051628 (2001-12-01), Huang et al.
patent: 2002/0010550 (2002-01-01), Grass et al.
patent: 2002/0012641 (2002-01-01), Voorhees et al.
patent: 2002/0013334 (2002-01-01), Robl et al.
patent: 2002/0013662 (2002-01-01), Grass et al.
patent: 2002/0014408 (2002-02-01), Schroeder
patent: 2002/0018988 (2002-02-01), Klinck et al.
patent: 2002/0028779 (2002-03-01), High et al.
patent: 2002/0028826 (2002-03-01), Robl et al.
patent: 2002/0042423 (2002-04-01), Richert et al.
patent: 2002/0061901 (2002-05-01), Robl et al.
patent: 2002/0072526 (2002-06-01), Fraley et al.
patent: 2002/0086791 (2002-07-01), Iglesia et al.
patent: 2002/0115858 (2002-08-01), Zimmermann et al.
patent: 2002/0147214 (2002-10-01), Cockerill et al.
patent: 2003/0087881 (2003-05-01), Bridges
patent: 2003/0125343 (2003-07-01), Gambacorti-Passerini et al.
patent: 2003/0130286 (2003-07-01), Denny et al.
patent: 2003/0153755 (2003-08-01), Moffat et al.
patent: 2003/0212269 (2003-11-01), Davis et al.
patent: 2004/0092747 (2004-05-01), Bender et al.
patent: 2004/0102453 (2004-05-01), Buerger et al.
patent: 2004/0224968 (2004-11-01), Seidelmann et al.
patent: 2004/0235786 (2004-11-01), Orr
patent: 2005/0192884 (2005-09-01), Raines
patent: 0 225 726 (1987-06-01), None
patent: 600832 (1993-11-01), None
patent: 0722937 (1996-01-01), None
patent: 05058894 (1993-03-01), None
patent: 11080131 (1999-03-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 97/03069 (1997-01-01), None
patent: WO 97/13760 (1997-04-01), None
patent: WO 99/09016 (1999-02-01), None
patent: WO 00/18740 (2000-04-01), None
patent: WO 00/50032 (2000-08-01), None
patent: WO 01/12227 (2001-02-01), None
patent: WO 01/25220 (2001-04-01), None
patent: WO 01/70741 (2001-09-01), None
patent: WO 00/61186 (2002-10-01), None
patent: WO 2004/011456 (2004-02-01), None
patent: WO 2004/011456 (2004-05-01), None
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Eliel, Ernest L., Wilen, Samuel H., Mander, Lewis N., “Stereochemistry of Organic Compounds”; A Wiley-Interscience Publication, John Wiley & Sons, Inc., pp. 1119-1190., 1994.
Monks, et al. J. Natl. Cancer Institute 83(11):757-66, 1991 Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
Bolen Oncogene, 8:2025-2031 (1993).
Plowman, et al., “Receptor Tyrosine Kinases as Targets for Drug Intervention”, DN&P 7(6):334-339, 1994.
Attoub, et al.; The c-kit Tyrosine Kinase Inhibitor ST1571 for Colorectal Cancer Therapy; Cancer Research 623, 4879-4883, Sep. 1, 2002.
Decaudin, et al.; In vivo Efficacy of ST1571 in Xenografted Human Small Cell Lung Cancer Alone or Combined with Chemotherapy; Int. J. Cancer: 113, 849-856; 2005.
Le Coutre, et al.; In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor; Journal of the National Cancer Institute; vol. 91, No. 2; Jan. 20, 1999.
Lev, et al.; Inhibition of Platelet-Derived Growth Factor Receptor Signaling Restrictions the Growth of Human Breast Cancer in the Bone of Nude Mice; Clinical Cancer Research; vol. 11, 306-314, Jan. 1, 2005.
Zwick, et al.; Receptor Tyrosine Kinases as Targets for Anticancer Drugs; Trends In Molecular Medicine; vol. 8, No. 1; Jan. 2002; 17-23.
Krause, et al.; Tyrosine Kinases as Targets for Cancer Therapy; New England Journal of Medicine; 353;2; Jul. 14, 2005; 172-187.
Brown Martyn
Danter Wayne R.
Houldsworth Stephen
Lazarowych Natalie
Ma George
Critical Outcome Technologies, Inc.
Rao Deepak
Thomas Kayden Horstemeyer & Risley LLP
LandOfFree
Protein tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein tyrosine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090324